S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$39.24
+3.67 (+10.32%)
(As of 03/28/2024 ET)
Today's Range
$35.16
$39.96
50-Day Range
$6.92
$47.08
52-Week Range
$3.03
$49.87
Volume
234,957 shs
Average Volume
948,959 shs
Market Capitalization
$412.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.00

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.5% Upside
$52.00 Price Target
Short Interest
Healthy
3.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.78mentions of Corbus Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$33.37 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.21) to ($5.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.68 out of 5 stars

Medical Sector

89th out of 938 stocks

Pharmaceutical Preparations Industry

33rd out of 432 stocks

CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

CRBP Factor-Based Stock Analysis
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
CRBP Apr 2024 25.000 put
CRBP Mar 2024 45.000 put
CRBP Jun 2024 50.000 put
CRBP Jun 2024 50.000 call
All Three of Our Analysts Agree
CRBP Mar 2024 40.000 call
Corbus Pharmaceuticals just upgraded at Jefferies, here's why
Corbus Pharmaceuticals Names Dominic Smethurst CMO
Corbus Pharmaceuticals Holdings Inc (3371.MU)
ACAD Mar 2024 35.000 put
ACAD Mar 2024 36.000 call
Corbus Pharmaceuticals Holdings Inc
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBP
Employees
19
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$52.00
High Stock Price Target
$58.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+45.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-44,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
($1.56) per share

Miscellaneous

Free Float
9,793,000
Market Cap
$374.68 million
Optionable
Optionable
Beta
2.43

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $46.00 to $58.00. On average, they anticipate the company's share price to reach $52.00 in the next year. This suggests a possible upside of 32.5% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2024?

Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of the year. Since then, CRBP stock has increased by 549.7% and is now trading at $39.24.
View the best growth stocks for 2024 here
.

Are investors shorting Corbus Pharmaceuticals?

Corbus Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 403,800 shares, an increase of 560.9% from the February 29th total of 61,100 shares. Based on an average daily volume of 886,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 3.9% of the shares of the company are short sold.
View Corbus Pharmaceuticals' Short Interest
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to analyst estimates of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (0.23%), Dimensional Fund Advisors LP (0.38%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners